ME Therapeutics Holding (FRA:Q9T) Other Current Liabilities: €0.00 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:Q9T ME Therapeutics Holding Inc FRA:Q9T
14 GF Score
Price €0.88
! 1 Warning Sign
View Full Analysis

What is ME Therapeutics Holding Other Current Liabilities?

ME Therapeutics Holding FRA:Q9T 14 Other Current Liabilities is €0.00 Mil as of May. 2026. GuruFocus rates FRA:Q9T with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

ME Therapeutics Holding's other current liabilities for the quarter that ended in May. 2026 was €0.00 Mil.

ME Therapeutics Holding's quarterly other current liabilities declined from Nov. 2025 (€0.00 Mil) to Feb. 2026 (€0.00 Mil) and declined from Feb. 2026 (€0.00 Mil) to May. 2026 (€0.00 Mil).

ME Therapeutics Holding's annual other current liabilities declined from Aug. 2023 (€0.00 Mil) to Aug. 2024 (€0.00 Mil) but then stayed the same from Aug. 2024 (€0.00 Mil) to Aug. 2025 (€0.00 Mil).

ME Therapeutics Holding Other Current Liabilities Related Terms

ME Therapeutics Holding Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for ME Therapeutics Holding's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding Other Current Liabilities Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24 Aug25
Other Current Liabilities
0.00 0.00 0.00 0.00

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:Q9T
14GF Score
ME Therapeutics Holding Inc FRA:Q9T
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ME Therapeutics Holding Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €0.00 Mil mean?
ME Therapeutics Holding (FRA:Q9T) has a Other Current Liabilities of €0.00 Mil as of May. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ME Therapeutics Holding.
Is ME Therapeutics Holding's Other Current Liabilities too high?
ME Therapeutics Holding's current Other Current Liabilities is €0.00 Mil. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Other Current Liabilities compare to VRTX and REGN?
ME Therapeutics Holding's Other Current Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on ME Therapeutics Holding. ME Therapeutics Holding's current Other Current Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (FRA:Q9T) has a current Other Current Liabilities of €0.00 Mil. The current Other Current Liabilities is €0.00 Mil. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For ME Therapeutics Holding (FRA:Q9T), the current Other Current Liabilities is €0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ME Therapeutics Holding Business Description

Other Exchanges METX:Canada
Address 2665 East Mall, Room 249, Vancouver, BC, CAN, V6T 1Z4
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score

Get the complete analysis for FRA:Q9T

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price